While we have observed small differences in terms of absolute uptake in tumor and normal organs between the L19-TNF alone or in combination with the RIPK1 inhibitor GSK’963, the tumor-selectivity for the immunocytokine was preserved. Here, RIPK1 is linked to neoplasm.